日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

The TALAPRO-3 study design: a plain language summary

TALAPRO-3 研究设计:简明语言概述

Agarwal, Neeraj; Saad, Fred; Azad, Arun A; Mateo, Joaquin; Matsubara, Nobuaki; Shore, Neal D; Chakrabarti, Jayeta; Chen, Hsiang-Chun; Lanzalone, Silvana; Niyazov, Alexander; Fizazi, Karim

Understanding and Deterring Online Child Grooming: A Qualitative Study

了解和阻止网络儿童性诱骗:一项定性研究

Wefers, Sarah; Dieseth, Therese; George, Emily; Øverland, Ida; Jolapara, Jayeta; McAree, Ciara; Findlater, Donald

Neoadjuvant Talazoparib in Patients With Germline BRCA1/2 Mutation-Positive, Early-Stage Triple-Negative Breast Cancer: Results of a Phase II Study

新辅助他拉唑帕尼治疗携带生殖系 BRCA1/2 突变的早期三阴性乳腺癌患者:一项 II 期研究的结果

Litton, Jennifer K; Beck, J Thaddeus; Jones, Jason M; Andersen, Jay; Blum, Joanne L; Mina, Lida A; Brig, Raymond; Danso, Michael; Yuan, Yuan; Abbattista, Antonello; Noonan, Kay; Niyazov, Alexander; Chakrabarti, Jayeta; Czibere, Akos; Symmans, William F; Telli, Melinda L

Carvedilol targets β-arrestins to rewire innate immunity and improve oncolytic adenoviral therapy

卡维地洛靶向 β-抑制蛋白,重塑先天免疫,改善溶瘤腺病毒疗法

Joseph I Hoare, Bleona Osmani, Emily A O'Sullivan, Ashley Browne, Nicola Campbell, Stephen Metcalf, Francesco Nicolini, Jayeta Saxena, Sarah A Martin, Michelle Lockley

Evaluation of pharmacokinetics and safety of talazoparib in patients with advanced cancer and varying degrees of hepatic impairment

评估他拉唑帕尼在晚期癌症合并不同程度肝功能损害患者中的药代动力学和安全性。

Guo, Cen; Yu, Yanke; Chakrabarti, Jayeta; Piha-Paul, Sarina A; Moroose, Rebecca; Plotka, Anna; Shi, Haihong; Durairaj, Chandrasekar; Wang, Diane D; Wainberg, Zev A

Chloroxine overrides DNA damage tolerance to restore platinum sensitivity in high-grade serous ovarian cancer

氯霉素可克服 DNA 损伤耐受性,恢复高级别浆液性卵巢癌的铂敏感性

Vera L Silva, Jayeta Saxena, Francesco Nicolini, Joseph I Hoare, Stephen Metcalf, Sarah A Martin, Michelle Lockley

The Effect of Renal Impairment on the Pharmacokinetics and Safety of Talazoparib in Patients with Advanced Solid Tumors

肾功能损害对晚期实体瘤患者服用他拉唑帕尼的药代动力学和安全性的影响

Durairaj, Chandrasekar; Chakrabarti, Jayeta; Ferrario, Cristiano; Hirte, Holger W; Babu, Sunil; Piha-Paul, Sarina A; Plotka, Anna; Hoffman, Justin; Shi, Haihong; Wang, Diane D

Talazoparib in Patients with a Germline BRCA-Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA Trial

Talazoparib治疗携带生殖系BRCA突变的晚期乳腺癌患者:来自III期EMBRACA试验的详细安全性分析

Hurvitz, Sara A; Gonçalves, Anthony; Rugo, Hope S; Lee, Kyung-Hun; Fehrenbacher, Louis; Mina, Lida A; Diab, Sami; Blum, Joanne L; Chakrabarti, Jayeta; Elmeliegy, Mohamed; DeAnnuntis, Liza; Gauthier, Eric; Czibere, Akos; Tudor, Iulia Cristina; Quek, Ruben G W; Litton, Jennifer K; Ettl, Johannes

MEK1/2 inhibitor withdrawal reverses acquired resistance driven by BRAFV600E amplification whereas KRASG13D amplification promotes EMT-chemoresistance

MEK1/2 抑制剂停药可逆转由 BRAFV600E 扩增驱动的获得性耐药性,而 KRASG13D 扩增则促进 EMT 化学耐药性

Matthew J Sale, Kathryn Balmanno, Jayeta Saxena, Eiko Ozono, Katarzyna Wojdyla, Rebecca E McIntyre, Rebecca Gilley, Anna Woroniuk, Karen D Howarth, Gareth Hughes, Jonathan R Dry, Mark J Arends, Pilar Caro, David Oxley, Susan Ashton, David J Adams, Julio Saez-Rodriguez, Paul D Smith, Simon J Cook1

Evaluation of hepatic impairment on pharmacokinetics and safety of crizotinib in patients with advanced cancer

评估肝功能损害对晚期癌症患者克唑替尼药代动力学和安全性的影响

El-Khoueiry, Anthony B; Sarantopoulos, John; O'Bryant, Cindy L; Ciombor, Kristen K; Xu, Huiping; O'Gorman, Melissa; Chakrabarti, Jayeta; Usari, Tiziana; El-Rayes, Bassel F